ELV — Deck
Elevance Health is the second-largest US managed-care insurer, covering roughly 45 million members across commercial, Medicare, and Medicaid plans — and the exclusive Blue Cross or Blue Cross Blue Shield licensee in 14 states.
Q1's 'trough confirmed' print may be a seasonality trap
Q1 has been Elevance's seasonal peak for three straight years, with full-year operating margin landing 2 to 3 percentage points lower as Q4 claims catch-up flows through. A 3.99% Q1 — the weakest in four years — applied to that same gap implies full-year FY26 around 2.85%, below FY25's 3.33% trough. The Street took the print as inflection on April 22 and raised the floor to $26.75; that requires the seasonal pattern to break for the first time since 2023. Q2, due late July, is the test.
Earnings rose 24% over five years; free cash flow fell 67%
A managed-care insurer should generate $1.20 to $1.40 of free cash for every dollar of GAAP profit because float and reserves run in its favor. Elevance's ratio collapsed to 0.56× in FY25 as receivables doubled from $11B to $21.5B over five years and days payable moved the wrong way. The $4.4B returned to shareholders in FY24 was funded by a $7.7B debt raise; FY25's $4.1B in capital return again exceeded FCF. Interest coverage halved from 8.9× to 4.7× — the lowest reading since 2008.
$935M for historical Medicare coding — a multi-year overhang, not a one-off
- The Q1 26 accrual covers risk-adjustment data disputes from 2015 to April 2023. Days in claims payable jumped from 41.3 to 46.6 in a single quarter. Disclosed exposure runs to $1.5B. Mentions of CMS RADV on earnings calls went from zero to nine in one quarter.
- Kaiser settled $556M on the same theory January 14, 2026 — the largest Medicare risk-adjustment FCA resolution on record. The DOJ–Anthem chart-review case is in active fact discovery, closing June 30, 2026, with no public reserve disclosed. Two parallel tracks; one accrual on the books.
- Adjusted EPS of $30.29 includes $3.75 per share that management itself called nonrecurring — the effective tax rate fell from 24.5% to 15.6% on a one-time restructuring benefit. True earnings power is closer to $26.50, already below FY24's $33.04, so trailing P/E on real earnings is 13.4×, not 11.8×.
Three external, dated tests inside a single quarter
- July 31 — CMS RADV compliance deadline (twice extended). A clean attestation acceptance with the final settlement at or below $935M and no prior-period restatement language eliminates the largest single regulatory tail. If sanctions take effect, the Cigna 2016 precedent is a 14% Medicare Advantage membership loss the following year.
- ~July 22 — Q2 FY26 earnings, roughly nine days inside the CMS deadline. The bear's trigger is the medical loss ratio drifting toward 88%, Medicaid worse than the −1.75% guide, or ACA retention below 1.2M. The bull needs a second sub-88% MLR print with operating margin above 4%.
- June 30 — DOJ v. Anthem fact discovery closes. A pre-trial settlement could land in Q2 or Q3 2026, layering a second accrual on top of the $935M. Expert discovery closes March 8, 2027 — the tail is real.
Lean cautious — the math says wait for Q2
- For. 2027 Star Ratings already locked in: 4+ Star members jumped from 40% to 59% in the October 2025 release. A hard-coded, regulation-set tailwind worth several hundred million in 2027 premium that no commentary can re-rate.
- For. CEO Boudreaux personally bought $2.4M on the open market in July 2025 at ~$290; three directors added $3.7M total across 18 months. Five insider buys at prices ~18% below today is unusual at a megacap insurer.
- For. Net cash $4B, Altman Z 3.03, EV/EBITDA 8.7× against UNH 13.1× — the widest gap in 15 years. Multiple is priced for the cycle, not for a broken franchise.
- Against. Q1's 3.99% is the lowest Q1 in four years; the seasonality math points to full-year FY26 op margin below FY25's 3.33% trough.
- Against. Capital return is bond-funded — $7.7B of debt issuance plugged the FY24 buyback gap; interest coverage at a 17-year low; FCF/NI 0.56×.
- Against. The $935M may not cap regulatory exposure; the Kaiser precedent and the DOJ–Anthem timing argue for a second, separately-reservable accrual the trailing multiple does not contemplate.
Watchlist to re-rate: Q2 operating margin and MLR (does it hold above 4% with MLR sub-88%); CMS RADV final settlement size and any prior-period language by July 31; days in claims payable trajectory — back toward 41d, or above 48d signaling a second accrual.